http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg
.trig | .trig.txt | .jelly | .jelly.txt
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix ns1: <https://w3id.org/np/o/ntemplate/> .
@prefix this: <http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg> .
@prefix sub: <http://purl.org/np/RAAkalv7pZ8gTBBmkdxnboav3S6Iz8oIRCQmF-UORj0gg#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:Head {
this: a np:Nanopublication;
np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo .
}
sub:assertion {
<http://purl.obolibrary.org/obo/DOID_2089> biolink:category biolink:Disease .
sub:association a rdf:Statement;
rdf:object <http://purl.obolibrary.org/obo/DOID_2089>;
rdf:predicate biolink:treats;
rdf:subject <https://identifiers.org/drugbank:DB00969>;
rdfs:label "\"Do not initiate in patients with constipation ( 4.1 History of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn's disease or ulcerative colitis; diverticulitis; severe hepatic impairment ( 4.2 Concomitant use of fluvoxamine ( 4.3 Alosetron hydrochloride tablets should not be initiated [see Warnings and Precautions ( 5.1 Alosetron hydrochloride tablets are contraindicated in patients with a history of the following: chronic or severe constipation or sequelae from constipation intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions ischemic colitis, impaired intestinal circulation, thrombophlebitis, or hypercoagulable state Crohn's disease or ulcerative colitis diverticulitis severe hepatic impairment Concomitant administration of alosetron hydrochloride tablets with fluvoxamine is contraindicated. Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1\"";
biolink:provided_by <https://w3id.org/um/NeuroDKG>;
biolink:relation schema:MedicalContraindication .
<https://identifiers.org/drugbank:DB00969> biolink:category biolink:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "LnC3Emo87wUNfcb0vhs1TD0thVmLqipYJ87sKmsfDwzY82hqp+XGUmTeamNruYc6kgpS/azVEIg0Fp3ncUOtpiiCWMRk0Qh4Pz1ZCsBb9F7MqpILtS76mETqoG2Am7LzMaA85GkVjT86Lo4JW9NKigf6udU9Nk8GZZ9BBDuU1W0=";
npx:hasSignatureTarget this: .
this: dct:created "2021-08-23T18:51:56.157+02:00"^^xsd:dateTime;
dct:creator orcid:0000-0002-1468-3557;
ns1:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
ns1:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}